Sinovac appoints Kenneth Lee to its board
This article was originally published in Scrip
Sinovac Biotech, a provider of biopharmaceutical products in China, has appointed Kenneth Lee to its board of directors to replace Xianping Wang. Mr Lee has been a principalat growth capital fund, SAIF Partners since 2007 and has more than 15 years' experience in private equity investment, corporate finance and business development in China.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.